𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝗶𝗻𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆, 𝗻𝗼𝘁 𝗽𝗿𝗶𝗺𝗮𝗿𝘆 𝗳𝗮𝗶𝗹𝘂𝗿𝗲, 𝗱𝗿𝗶𝘃𝗲𝘀 𝗺𝗼𝘀𝘁 𝗮𝗱𝗮𝗹𝗶𝗺𝘂𝗺𝗮𝗯 𝘀𝘁𝗼𝗽𝘀 𝗶𝗻 𝗕𝗲𝗵𝗰𝗲𝘁’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 In a single-centre retrospective chart review of 335 patients with Behçet’s syndrome who started adalimumab between 2008 and 2023, adalimumab showed good early persistence that declined gradually over time. All discontinuations were counted as events, regardless of cause. • 𝗥𝗲𝘁𝗲𝗻𝘁𝗶𝗼𝗻. Rates were 88.9% at 6 months, 78.3% at 12 months and 67.1% at 24 months. Over a mean follow-up of 26.6 months (SD 23), 137 patients (41%) stopped adalimumab. • 𝗥𝗲𝗮𝘀𝗼𝗻𝘀 𝗳𝗼𝗿 𝘀𝘁𝗼𝗽𝗽𝗶𝗻𝗴. Inefficacy was the leading cause, mainly secondary loss of response; primary inefficacy was uncommon. Adverse events, non-compliance, remission and other reasons followed. • 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗼𝗿𝘀. Discontinuation was not significantly associated with age, sex, disease duration, prior tumour necrosis factor inhibitor use, concomitant conventional DMARD use, or major organ involvement. • 𝗗𝗼𝘀𝗲 𝗮𝗱𝗷𝘂𝘀𝘁𝗺𝗲𝗻𝘁. Interval extension in 36 patients with sustained remission led to relapse or flare in 5 (14%); all regained remission after the dose was restored. Dose intensification in 30 patients with active disease produced remission in 17 (56.6%). • 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻. Early retention is high, then falls mainly because of secondary inefficacy, adverse events and non-compliance. Both dose escalation for incomplete control and cautious de-escalation in sustained remission appear feasible. *Sonmez O, Esatoglu SN, Ucar D, et al. Drug survival of adalimumab across different manifestations of Behçet’s syndrome: a retrospective analysis in 335 patients. Rheumatology (Oxford). 2026;65(10):keag510. 🔗doi.org/10.1093/rheumatology…

Sex differences with bimekizumab in axSpA: earlier gain in men, convergence by Week 52 Post-hoc sex analysis of bimekizumab (BKZ; dual IL-17A/F inhibitor) in the phase 3 BE MOBILE trials: BE MOBILE 1 (nr-axSpA, NCT03928704) and BE MOBILE 2 (r-axSpA, NCT03928743), through Week 52. Population. Sex balance differed by phenotype: nr-axSpA was roughly balanced (54.3% male); r-axSpA was male-predominant (72.3% male). At baseline, males generally had higher objective inflammation (MRI, hs-CRP), while females tended to report worse health-related quality of life (e.g. higher ASQoL). Week 16 (BKZ vs placebo). Treatment effect versus placebo was typically larger in men than in women on composite and patient-reported outcomes: ASAS40, ASDAS <2.1, BASDAI, BASFI, pain, fatigue, and HRQoL. That pattern held across both nr- and r-axSpA. Week 52 (BKZ-randomised patients). Responses were sustained or continued to improve in both sexes. Women showed clear longer-term gains, narrowing the early gap, though absolute rates often remained numerically higher in men—especially in nr-axSpA. Conference-reported Week 52 rates in BKZ-randomised patients (male vs female): • ASAS40: nr-axSpA 64.4% vs 56.4%; r-axSpA 59.4% vs 55.7% • ASDAS <2.1: nr-axSpA 72.0% vs 47.4%; r-axSpA 57.7% vs 55.8% • Mean BASDAI change: nr-axSpA −4.0 vs −3.6; r-axSpA −3.6 vs −3.4 ASQoL also improved substantially in both sexes by Week 16 and further by Week 52 (in some arms the Week 52 ASQoL gain was larger in women). Objective inflammation. Despite higher baseline MRI inflammation and hs-CRP in men, both sexes reached similarly low levels by Week 16, maintained through Week 52. Absolute MRI and hs-CRP values converged even when the Week 16 placebo-controlled difference favoured men. Takeaway. Men tended to respond earlier on clinical and patient-reported measures. Women caught up over the year, with substantial longer-term improvement. Suppression of objective inflammation was robust and comparable in both sexes by Week 16 and 52. Efficacy was shown across the full axSpA spectrum in both sexes. *Rudwaleit M, Ramiro S, Poddubnyy D, et al. Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE trials. Rheumatology (Oxford). Published online August 14, 2026. 🔗doi.org/10.1093/rheumatology…